Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Why Novavax (NVAX) Dipped More Than Broader Market Today
Novavax (NVAX) closed at $7.26 in the latest trading session, marking a -1.76% move from the prior day.
Novavax (NVAX) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Novavax (NVAX) stood at $7.91, denoting a -0.57% change from the preceding trading day.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying
Buying stocks after they have lost significant market value can lead to excellent returns in the long run, but only if the company in question can reverse its fortunes.
Novavax, Inc. (NVAX) Leerink Partners 2025 Global Healthcare Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX ) Leerink Partners 2025 Global Healthcare Conference March 11, 2025 12:00 AM ET Company Participants John Jacobs - CEO Ruxandra Draghia - Head of R&D Jim Kelly - CFO Conference Call Participants Dave Risinger - SVB Leerink Dave Risinger All righty, well thank you everybody for joining and for those of you who don't know me, my name is Dave Risinger and I'm very much pleased to welcome a number of members of the Novavax senior leadership team to be with us here today. Thank you for making the trip to Miami.
Novavax, Inc. (NVAX) TD Cowen 45th Annual Health Care Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX ) TD Cowen 45th Annual Health Care Conference March 4, 2025 9:10 AM ET Company Participants John Jacobs - President and Chief Executive Officer Ruxandra Draghia - Executive Vice President & Head of Research & Development Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Chris LoBianco - TD Cowen Chris LoBianco Great. So I think we'll get started.
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc.'s Q4 2024 earnings — released yesterday — show a significant revenue decline and continued losses, despite cost-cutting measures and the deal with Sanofi, worth up to $1.2bn. The company's future hinges on the approval of its Biologics License Application this April, triggering a $175m milestone from Sanofi, and the success of its partnership with Sanofi, amidst regulatory uncertainties. Novavax aims to achieve profitability by 2027 through cost reductions and potential milestone payments from Sanofi's CIC vaccine launch, but the overall picture does not inspire too much confidence.
1 Biotech Stock to Buy in 2025, and 1 to Avoid
Viking Therapeutics (VKTX 3.06%) and Novavax (NVAX -3.55%) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting clinical progress, while the latter signed a lucrative deal with a biotech giant that had Wall Street cheering.
Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates
NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo Nordisk for $200 million.
Novavax, Inc. (NVAX) Q4 2024 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development John Trizzino - President and Chief Operating Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Robert Walker - Senior Vice President and Chief Medical Officer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Securities Eric Joseph - JPMorgan Vernon Bernardino - H.C.
